How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.
How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.
复制标题
DOI：
10.1158/0008-5472.can-20-1420
复制
发表时间：
2020-10-01
期刊：
影响因子：
11.2
通讯作者：
Stanger BZ
中科院分区：
文献类型：
--
作者：
Li J;Stanger BZ
免疫疗法彻底改变了癌症治疗，但大多数患者没有反应。虽然有效的免疫治疗需要肿瘤抗原，但有利的肿瘤免疫微环境也至关重要。在这篇综述中，我们讨论了新出现的证据，表明肿瘤细胞利用细胞可塑性和去分化程序来避免免疫监视，这反过来又推动了转移性扩散和对免疫治疗的抵抗。对这些计划的更深入了解可能会为增强现有免疫疗法的功效提供新的机会。
Immunotherapy has revolutionized cancer treatment, yet most patients do not respond. While tumor antigens are needed for effective immunotherapy, a favorable tumor immune microenvironment is also critical. In this review, we discuss emerging evidence that tumor cells exploit cellular plasticity and dedifferentiation programs to avoid immune surveillance, which in turn drives metastatic dissemination and resistance to immunotherapy. A deeper understanding of these programs may provide novel opportunities to enhance the efficacy of existing immunotherapies.